Search This Blog

Friday, March 15, 2019

Neurocrine treatment of congenital adrenal hyperplasia gets orphan status

The FDA granted orphan designation to Neurocrine Biosciences’ treatment of congenital adrenal hyperplasia, according to a post to the agency’s website
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)